• Aucun résultat trouvé

diabetes type 1 and 2

Cannabinoid-1 receptor antagonists in type-2 diabetes.

Cannabinoid-1 receptor antagonists in type-2 diabetes.

... with type- 2 diabetes and a high risk of cardiovascular disease deserves ...RIO Diabetes and SERENADE demonstrate the therapeutic value of the CB1-receptor antagonist rimonabant ...

13

DPP-4 inhibitors in the treatment of type 2 diabetes.

DPP-4 inhibitors in the treatment of type 2 diabetes.

... therapy and has shown clinically meaningful improvement of glycaemic control in type 2 ...Fasting and 2h post-prandial glucose were significantly reduced in the linagliptin arm compared to ...

27

Skeletal muscle lipase content and activity in obesity and type 2 diabetes.

Skeletal muscle lipase content and activity in obesity and type 2 diabetes.

... freeze-dried and dissected free of all visible adipose tissue, connective tissue, and blood under a microscope and was subsequently homogenized (1:80 by volume), as de- scribed previously ...

6

Preventing and treating kidney disease in patients with type 2 diabetes

Preventing and treating kidney disease in patients with type 2 diabetes

... characteristics and sample size for ACE inhibitors) are available with ARA II in T2DM patients: IDNT [ 37 ] and RENAAL [ 38 ] ( Table 2 ...mg/dL and 1.9 mg/dL and significant (macro) ...

19

Skin autofluorescence predicts cancer in subjects with type 2 diabetes

Skin autofluorescence predicts cancer in subjects with type 2 diabetes

... Results The participants were mainly men (57.9%), with poorly controlled (HbA1c 72±14 mmol/mol or 8.7%±1.8%) and/or complicated type 2 diabetes. Their median skin autofluorescence was 2.6 ...

8

Voglibose for prevention of type 2 diabetes mellitus.

Voglibose for prevention of type 2 diabetes mellitus.

... of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research ...

3

Thymus dysfunction in the development of type 1 diabetes and endocrine autoimmune diseases

Thymus dysfunction in the development of type 1 diabetes and endocrine autoimmune diseases

... More and more experimental arguments argue for a defect in thymic (central) tolerogenic function as an initial event in the development of organ-specific autoimmune diseases such as type 1 ...

3

Which incretin-based therapy for type 2 diabetes?

Which incretin-based therapy for type 2 diabetes?

... Dungan and colleagues, dulaglutide at a dose of ...albiglutide and dulaglutide because sample size, demographic characteristics, background glucose-lowering therapies and baseline HbA1c were rather ...

7

Addition of incretin therapy to metformin in type 2 diabetes.

Addition of incretin therapy to metformin in type 2 diabetes.

... of type 2 diabetes: a randomised, open-label, non-inferiority ...control and weight reduction compared to sitagliptin and pioglitazone after 26 weeks of ...American Diabetes ...

3

Pulse pressure and cardiovascular autonomic neuropathy according to duration of type 1 diabetes.

Pulse pressure and cardiovascular autonomic neuropathy according to duration of type 1 diabetes.

... [5] and a higher mortality [12] in the large EURODIAB cohort of T1DM ...patients. Diabetes duration-related (in the diabetic population) and age-related (in the non-diabetic population) changes in ...

11

Pharmacological management of type 2 diabetes: what's new in 2017?

Pharmacological management of type 2 diabetes: what's new in 2017?

... 7.5-8.4) and was higher for type 1 diabetes than for ...subpopulation and can occur at any duration of SGLT2i ...prescribing and throughout therapy if patients present with ...

36

Bariatric surgery in patients with Type 2 diabetes: benefits, risks, indications and perspectives.

Bariatric surgery in patients with Type 2 diabetes: benefits, risks, indications and perspectives.

... of type 2 diabetes (T2DM), and weight loss is a major objective, although difficult to achieve with medical ...marked and sustained weight loss, and is also associated with a ...

8

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

... a 2-compartment model with first- order ...absorbed and t max at steady state ranged from 24 to 72 hours (median = 48 ...47% and the half-life was estimated at ...between 2 and 4 weeks ...

32

‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

... adherence and physician clinical inertia, disease-specific factors may also contribute to PPDM in T2D, especially when the defect of insulin secretion cannot overcome insulin ...more and more difficult as the ...

3

Hyperglycemia, type 2 diabetes, and depressive symptoms: the British Whitehall II study.

Hyperglycemia, type 2 diabetes, and depressive symptoms: the British Whitehall II study.

... between type 2 diabetes and depression, both major public health challenges, remains unclear ...with type 2 diabetes had an increased risk of depressive symptoms, whereas, ...

13

Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?

Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?

... test and the minimal model approach, we also reported such acute favorable effect of metformin in a population similar to that of the DPP, ...only 1-2 weeks may be ...of diabetes, which ...

4

T Cell Populations and Functions Are Altered in Human Obesity and Type 2 Diabetes

T Cell Populations and Functions Are Altered in Human Obesity and Type 2 Diabetes

... obesity and T2D are tightly linked, patients exhibit different medical trajectories and ...phenotype, and a decrease of peripheral unconventional T cells (Table ...obesity and T2D and ...

20

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

... + and CD8 + pancreas-infiltrating T cells but no change in the PLN of prediabetic treated animals ...cells and to a lesser extent in PLN CD4 + T cells ...to diabetes (Feuerer et ...acid, and ...

9

Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes

Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes

... bias), and inclusion of well characterized cohort studies (facilitating an assessment of the independent effects of ...of type 2 diabetes varied between the ...with diabetes over the ...

27

Thymus and Type 1 diabetes: Where are we now?

Thymus and Type 1 diabetes: Where are we now?

... that: 1° IGF-2 is the dominant tolerogenic precursor of the family and mediates cross- tolerance to insulin; 2° A thymus dysfunction plays a crucial role in the development of the diabetogenic ...

1

Show all 10000 documents...

Sujets connexes